Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675535 | 0.91 | TTR (0.55) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL943514 | 0.87 | HDAC6 (0.77) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675286 | 0.86 | HPSE (0.61) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675296 | 0.85 | ALDH1A1 (0.67) | HDAC6P2RY14MAPTHPSEKDM4E | |
| SCHEMBL1675525 | 0.83 | HDAC6 (0.63) | HDAC6MAPTHPSEKDM4ENPC1 | |
| SCHEMBL439112 | 0.82 | HDAC6 (0.58) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL445014 | 0.80 | HDAC6 (0.74) | HDAC6HDAC3HDAC1HDAC8MAPT | |
| SCHEMBL11564007 | 0.78 | HPSE (0.66) | HDAC6MAPTHPSEKDM4ENPC1 | |
| SCHEMBL14403511 | 0.78 | TTR (0.58) | HDAC6MAPTHPSENPC1ALDH1A1 | |
| SCHEMBL1675550 | 0.78 | HDAC6 (0.64) | HDAC6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | claimed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | claimed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8633019-B2 | Methods for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | THERAPEUTICS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2007117438-A2 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | HDAC6 161/4885HDAC3 1363/4885HDAC1 1342/4885 |
| US-20110046136-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH | UPF1, DNAJC10, RNGTT | HDAC6 2201/4885HDAC3 4125/4885HDAC1 3659/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | HDAC6 2371/4885HDAC3 4224/4885HDAC1 3787/4885 |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, NSUN2, RNMT | HDAC6 836/4885HDAC3 2726/4885HDAC1 2234/4885 |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | HDAC6 161/4885HDAC3 1363/4885HDAC1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.